Tago 1990.

Methods	RCT. Placebo controlled, parallel design. Double‐blind. Masking of assessors not stated. Multicentre (41).
Participants	142 patients. Inclusion criteria: Neurogenic bladder and unstable bladder with uninhibited detrusor contraction, pollakisuria and UI.
Interventions	Group 1: propiverine 20mg od (n=?) Group 2: placebo (n=?) 2 week treatment period.
Outcomes	Subjective symptoms, global improvement rating, global utility rating. Urodynamic parameters. Adverse events
Notes	Abstract. Group numbers not reported. Dropouts not reported. Data not in useable form for this review.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Low risk	A ‐ Adequate